OTS - First product based on LTS' SorrelTM wearable drug delivery platform launched in the US
2024. February 28. 13:00
Andernach, 28 February, 2024 (APA/OTS) - LTS LOHMANN
Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology
company, announced today that its customer Coherus BioSciences, Inc
("Coherus") has launched its UDENYCA® on-body injector (OBI)
utilizing the LTS SorrelTM wearable drug delivery platform.)
UDENYCA® (pegfilgrastim-cbqv) is a biosimilar pegfilgrastim
administered the day after chemotherapy to decrease the incidence
of infection as manifested by febrile neutropenia. The UDENYCA® OBI
has received approval from the U.S. Food and Drug Administration
(FDA) in December 2024. The device sets new standards for
performance, quality, reliability, and patient convenience in
wearable injection devices.
Coherus and LTS have been working in partnership to receive
approval for the delivery of Udenyca® OBI. The novel drug delivery
device platform will assist Udenyca® patients in receiving the drug
in the comfort of their home and is intended to lower a patient's
risk of infection after they have received chemotherapy.
Bas van Buijtenen, CEO of LTS, commented: "This launch
completes the market entry of LTS into Biologics, bringing the ease
of administration that LTS's solutions are known for to new class
of therapies. Our capacity is ready to scale up, providing access
to this advantageous solution to all patients swiftly."
"The approval by the U.S. FDA was a clear vote of confidence
and an important milestone for the SorrelTM platform. The launch
shows our capability to manufacture and delivery according to
market needs," said Dr. Andrei Yosef, President and General Manager
of LTS Device Technologies. "Approval and launch will accelerate
our other partnered programs running on the same platform, as well
as programs with partners looking to obtain market access in the
future."
About SorrelTM
The SorrelTM technology allows pre-filled, pre-loaded and
pre-assembled wearable drug delivery device that provides an
easy-to-use wearable device for at home administration. The
SorrelTM platform ranges from 1mL to 50 mL and is primary container
agnostic to provide seamless integration into the pharma company
product.
About LTS
We CARE. We CREATE. We DELIVER. The driving philosophy behind
LTS. As a trusted technology partner for the pharmaceutical
industry, we develop and manufacture innovative drug delivery
systems such as Transdermal Patches ("TTS") and Oral Thin Films
("OTF") as well as wearable drug delivery devices ("OBDS"). LTS´
commercial offering encompasses more than 20 marketed products and
a diverse pipeline of more than 40 development projects targeting
multiple disease indications. LTS's innovation pipeline contains
both partner-funded as well as proprietary, LTS-funded projects.
LTS maintains its leading position through the continuous
refinement of its core TTS and OTF technologies and by advancing
emerging drug delivery technologies, including Microneedle Array
Patches ("MAP") for the transdermal delivery of small and large
molecules, biological actives and vaccines. With its SorrelTM
wearable drug delivery platform LTS offers patient friendly
solutions for complex drugs delivery at home. Founded in 1984, LTS
operates today from four sites: in Andernach, Germany, West
Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has
also a representative office in Shanghai, China.
- Picture is available at AP
(https://apmultimedianewsroom.com/multimedia-newsroom/partners/news-aktuell)
-
Dr Iris Schnitzler
iris.schnitzler@ltslohmann.com
+49 2632 992589
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.